Robotic assisted bronchoscopy
DeviceRobotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
Other names: Robotic assisted bronchoscopy with Monarch platform
NCT Number: NCT04182815
This study is designed to evaluate clinical safety and diagnostic accuracy of the robotic-assisted bronchoscopy with biopsy performed with the Monarch™ Endoscopy Platform in a broad range of patients with pulmonary lesions.
Looking for future studies?
Notify Me21 year and older
All sexes
Observational
University Health Network, Toronto, Ontario, Canada
Despite technological advancements in guided bronchoscopy such as electromagnetic navigation bronchoscopy and radial probe endobronchial ultrasound, successful biopsy of peripheral pulmonary lesions remains a challenge due to a number of factors, one of which may be the ability to gain access to peripheral lesions due to the size and maneuverability of conventional bronchoscopes. The diagnostic yield of conventional bronchoscopic approaches for peripheral lesions remains suboptimal.
A novel robotic assisted bronchoscopy procedure now exists for patients with lung nodules. This procedure is performed using the Monarch™ platform (Auris Health, Inc., Redwood City, CA). This study is expected to enroll up to 1200 patients at up to 30 investigative sites.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
Other names: Robotic assisted bronchoscopy with Monarch platform
Time frame: up to 7 days post procedure
The primary endpoint is a composite that includes pneumothorax requiring intervention rated as > Grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE) scale, bleeding requiring medical intervention, rated as > Grade 1 according to the CTCAE scale, and respiratory failure, rated as > Grade 3 according to the CTCAE scale.
Time frame: up to 7 days post procedure
Individual components of the primary endpoint
Time frame: up to 7 days post procedure
Time frame: During the procedure
Time frame: During the procedure
Time frame: up to 7 days post procedure
Time frame: up to 24 months post procedure
Stage at diagnosis (if applicable) will be evaluated for all robotic-assisted bronchoscopy procedures performed for suspicion of lung cancer
Time frame: up to 24 months post procedure
Diagnostic yield for all robotic-assisted procedure performed for suspicion of lung cancer will be evaluated based on histopathological assessment of acquired tissue samples
Time frame: up to 24 months post procedure
Time frame: up to 7 days post-procedure
Auris Health, Inc.
Industry
Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors
Acronym: TARGET
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05160571
Lung Cancer, Lung Diseases
Winchester, Virginia, United States
View Trial DetailsNCT06923774
Lung Cancer, Lung Diseases
Le Plessis-Robinson, France
View Trial DetailsNCT07467005
Lung Cancer, Lung Diseases
Hangzhou, Zhejiang, China
View Trial DetailsNCT06628102
Lung Cancer, Lung Diseases
Vancouver, British Columbia, Canada
View Trial Details